

Ascendis Health Limited
(Incorporated in the Republic of South Africa)
(Registration number: 2008/005856/06)
Share code: ASC
ISIN: ZAE000185005
("Ascendis" or "the Company")



TRADING STATEMENT FOR THE YEAR ENDED 30 JUNE 2024

In terms of the Listings Requirements of the JSE Limited, a listed company is required to publish a trading statement as soon as a reasonable degree of certainty exists that the financial results for the period to be reported on next will differ by 20% or more from the financial results for the previous published corresponding period.

It is best practice to adopt a cautious approach in relation to the compilation of quantitative explanations and considerations for financial results, including a trading statement. Practically and in terms of the JSE Listings Requirements, this means that issuers are required to provide disclosure of the forecasts, estimates and judgments by applying IFRS.

This is to ensure that disclosures are:

- * transparent;
- * not misleading;
- * understandable;
- * reliable;
- * consistently presented between reporting periods; and
- * does not obfuscate or detract from the financial information.

Accordingly, the board of directors of Ascendis advises shareholders that it is reasonably certain that the financial results for the year ended 30 June 2024 ("**Current Period**"), when compared with the published results for the year ended 30 June 2023 ("**Prior Corresponding Period**"), are expected to differ as follows;

Continuing Operations	30 June 2023 In cents	30 June 2024 Expected in cents	30 June 2024 Expected (decrease)/increase in %
Earnings/ (loss) per share	(47.2)	6.0 to 7.3	113% to 115%
Headline earnings/(loss) per share	(41.5)	(1.3) to (1.6)	96% to 97%

Total Operations	30 June 2023 in cents	30 June 2024 Expected in cents	30 June 2024 Expected (decrease)/increase in %
Earnings per share	12.4	8.2 to 10.1	(19%) to (34%)
Headline earnings/(loss) per share	(39.7)	0.9 to 1.2	102% to 103%

This trading statement is the responsibility of the directors and the financial information on which this statement is based has not been reviewed or reported on by the external auditors of the Company.

The expected publication date of the Company's condensed reviewed results is 03 September 2024.

Johannesburg
30 August 2024

Sponsor
Valeo Capital (Pty) Ltd

